OBJECTIVES: Autologous peripheral stem cell transplantation (ASCT) with high-dose chemotherapy is a preferred treatment for non-Hodgkin’s lymphoma (NHL) patients. Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G+P) is superior to G-CSF alone for stem cell mobilization (SCM) in heavily pretreated NHL patients. The main aim of this study was to perform comparative pharmacoeconomic analysis of using G+P versus G-CSF as a method for SCM.  METHODS: Analysis of the published clinical trials was conducted to evaluate comparative efficacy and safety of the studied therapy options. Taking into account the hypothesis of superior effectiveness of combination G+P for SCM for pharmacoeconomic analysis was chosen “cost-utility” analysis. For this study was adopted a Markov model simulated the care process of NHL patients undergoing ASCT using data from the Washington University site of the plerixafor Phase III study (Kymes SM. et al, 2012).  Direct medical costs included diagnosis, mobilization and remobilization costs, aphaeresis, CD34+ cell processing and cryopreservation. Mobilization and remobilization costs were defined to be the costs of medical procedures, resource utilization, and medications. The incremental cost-utility ratio (ICUR) was estimated. One-way sensitivity analysis was made. RESULTS: According to published trials the combination G+P has been shown to mobilize more CD34+ cells than G-CSF alone for ASCT. Additionally, G+P mobilization resulted in more predictable days of collection, no weekend aphaeresis procedures, and no unscheduled hospital admissions. The expected lifetime cost of providing care for NHL patients using G+P was 601 294 rubles ($11 227) more than G-CSF, but they accumulated 1.75 more quality adjusted life years (QALYs) for an ICUR of 343 596 rubles ($6 415)/QALY. The one-way sensitivity analysis showed that the results are more sensitive to the variations of key model parameter, such as price of plerixafor. CONCLUSIONS: Using G+P for SCM in ASCT of patients with NHL was more effective and economically justified treatment option.